Observations placeholder
Tekturna
Identifier
020187
Type of Spiritual Experience
Background
A description of the experience
Aliskiren (INN) (trade names Tekturna, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension. While used for high blood pressure, other better studied medications are typically recommended due to concerns of higher side effects and less evidence of benefit.
In December 2011, Novartis halted a clinical trial of the drug after discovering increased incidence of nonfatal stroke, kidney complications, high blood potassium, and low blood pressure in people with diabetes and kidney impairment
Adverse effects
- Angioedema
- High blood potassium level (particularly when used with ACE inhibitors in diabetic patients)
- Low blood pressure (particularly in volume-depleted patients)
- Diarrhea and other GI symptoms
- Headache
- Dizziness
- Cough
- Rash
- Elevated uric acid, gout, and kidney stones
On Feb, 11, 2016: 3,358 people reported to have side effects when taking Tekturna. Among them, 9 people (0.27%) have Hallucination.
Time on Tekturna when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
On Feb, 11, 2016: 3,358 people reported to have side effects when taking Tekturna. Among them, 51 people (1.52%) have Death.
Time on Tekturna when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 50.00% | 25.00% | 0.00% | 25.00% | 0.00% | 0.00% | 0.00% |